Most trials target relapsed or refractory (R/R) hematological cancers, such as acute lymphoblastic leukemia (ALL), NHL, and AML, with CD19 and CD33 being the most common target antigens. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.